Macro, macro, macro but now it is to the other way. We did have another big piece of news hit last night in terms of CLL, which I will talk.
While I wanted some more news from the biotech sector this was not exactly what I was planning. I discuss my thoughts on ARIA in an article on the street,.
Macro, macro, and more macro. That seems to be driving the market and without any significant biotech specific news that was the word of the day. As we get closer.
Outside of a weak day in the macro which appears mainly related to macro issues, there does not seem to be a ton of news. Biotechs were obviously weak with.
It was a fairly busy day today in biotech land the sentiment certainly appears more positive. They participated in the market rally even though most were not big losers in.
Not a particularly news rich day but the sector seemed to continue its momentum from yesterday and seemed to outperform the general market with a lot of green on a.
A very interesting and odd day in the market today. Overall the market continued its weakness and biotechs were generally down. The market came back and it seemed to turn.
Obviously the big news of the day was the failure of drisapersen in their phase III trial and what it means for etperlirsen and SRPT. While it is not clear.